A treatment that targets immune cells’ primary adenosine receptor.
At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
EOS-448 is a human immunoglobulin antibody that we are developing to inhibit the immunosuppressive activity of TIGIT, a cell receptor expressed on multiple immune cells, including CD8+ T cells, natural killer (NK) cells, and T regulatory cells (Tregs).
Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.
Latest press releases
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
– EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical…
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and P…
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical…